A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
NCT ID: NCT06884098
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
60 participants
INTERVENTIONAL
2025-03-10
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers
NCT06359626
Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers
NCT06613139
Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects
NCT06920719
Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers
NCT06775522
Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose
NCT06428903
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A (RT)
Period 1: Reference Drug (AD-2284), Period 2: Test Drug (AD-228B)
AD-228B
AD-228B, 1Tab., Per Oral
AD-2284
AD-2284, 1Tab., Per Oral
Sequence B (TR)
Period 1: Test Drug (AD-228B), Period 2: Reference Drug (AD-2284)
AD-228B
AD-228B, 1Tab., Per Oral
AD-2284
AD-2284, 1Tab., Per Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-228B
AD-228B, 1Tab., Per Oral
AD-2284
AD-2284, 1Tab., Per Oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H Plus Yangji Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-228BE-H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.